CPhI Worldwide Paris 2014

The key to market exclusivity? Forget molecules, patent your tests

Some drugmakers patent their patient screening tests

Makers of branded drugs are finding ways to extend their marketing authorisation by patenting not only molecules, but patient screening methods and ways of proving bioequivalence.

Doctors ask for quick-dissolve meds to stop in-patient cheating

Doctors ask for quick-dissolve meds to stop in-patient cheating

Some patients surveyed preferred taking effervescent medicines. (Picture: Raymond Gilford/Flickr)

A bitter pill to swallow: young people dislike tablets more than old

Pharma's demands from manufacturing partners more complex from the start, say Catalent and DPx

CDMO strategic deals 'the new standard,' say Catalent and DPx, but big and small pharma demands differ

PDPs attracting Big Pharma in Brazil says Jose Piccolotto, head of business development at Brazil's largest drugmaker EMS

Big Pharmas and API suppliers eyeing Brazilian Government deals says EMS

Indian Government compares recent success in its cut-price mission to Mars to drug manufacturing

Global regulators demanding needless drug quality levels, says Indian Gov

DSM makes statins like rosuvastatin, the API in Astrazeneca's Crestor, using enzymes

DSM cuts out China's ATS-8 intermediate middlemen with enzyme-made statin APIs

There is a shortage of aseptic capacity in the UK following issues at SCM pharma and capability U-turns, says Aesica

CDMOs: Leave aseptic manufacturing to the Vetters of this world, says Aesica

Halal: not just about food (Picture: Marco Bellucci/Flickr)

Halal: accessing the untapped $30bn pharma market

Sabic: Plastics to cut costs and up safety in single-use bioreactors

Sabic: Compatible plastics to cut costs and up safety in single-use bioreactors

More CPhI Worldwide Paris 2014